Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
IMPORTANT: This compound is currently on the World Anti-Doping Agency (WADA) prohibited list. Competitive athletes face sanctions for use including in retirement testing programs. Verify current WADA status with your sport's governing body before any research involvement.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.
GHRP-6 requires subcutaneous injection with a 28-31 gauge insulin syringe. Inject 100-300 mcg on empty stomach 2-3 times daily, 4-6 hours apart. Rotate injection sites (abdomen, thigh, arm) to prevent lipohypertrophy. Use 45-90 degree needle insertion at 1/4-1/2 inch depth with aspiration before injecting.
Injection Sites
Optimal sites: abdomen (1-2 inches lateral to navel), outer thigh, upper arm lateral surface, or hip/buttock. Abdominal injections absorb fastest. Rotate sites to prevent lipohypertrophy (fatty nodule development) and lipoatrophy. Maintain a rotation calendar.
Aseptic Technique
Wash hands 20+ seconds. Gather: reconstituted GHRP-6 vial, sterile insulin syringe (1 mL, 28-31 gauge), sterile needle, alcohol prep pads, gauze, sharps container. Inspect peptide for particulates or discoloration. Cleanse injection site with alcohol for 15-20 seconds using firm circular motions. Allow to air-dry 30 seconds.
Needle Insertion
Pinch skin to create 1/2 inch fold. Insert needle at 45-90 degree angle into subcutaneous fat layer. Insert 1/4 to 1/2 inch depending on body composition. Aspirate before injection to check for blood vessel penetration; if blood appears, withdraw and select different site.
Injection Procedure
Steadily depress plunger over 3-5 seconds. Rapid injection increases discomfort; slow injection reduces trauma. Withdraw needle and apply gentle pressure with gauze for 10-15 seconds to prevent leakage. Massage area gently 20-30 seconds to distribute peptide. Dispose of needle/syringe in sharps container; never recap needles.
Syringe Selection
Insulin syringes (1 mL, 100 IU) are gold standard: small gauge (28-31) and sharp beveled needles for accurate micro-dosing. Tuberculin syringes acceptable but larger gauge causes more discomfort. Use sterile single-use only—never reuse. Dullness after single injection increases next-use discomfort and infection risk.
Pain Management
GHRP-6 injections typically well-tolerated with minimal discomfort. Small-gauge needles (28-31) reduce trauma versus larger gauges. Topical anesthetic (EMLA cream applied 30 minutes prior) reduces discomfort for pain-sensitive users. Allow solution to warm to room temperature (10-15 minutes) to reduce discomfort versus cold injection.
Injection Timing and Frequency
GHRP-6 requires 2-3 daily injections due to short 2.5-hour elimination half-life. Standard protocol: 150 mcg at 6-7 AM, 200 mcg at 12-1 PM, 150 mcg at 6-7 PM on empty stomach spaced 4-6 hours apart. Empty stomach timing (30-60 minutes before/after) optimizes GH response by avoiding meal-induced glucose spikes that suppress GH. Evening injection should occur 3-4 hours before bedtime to avoid interfering with natural sleep-associated GH secretion.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →FAQ: Injection Technique
Blood appears when aspirating?
Withdraw immediately and select different site. This indicates blood vessel penetration. Always aspirate before injecting.
Can I reuse needles?
Not recommended. Needles dull after single injection, increasing discomfort and infection risk. Single-use sterile needles cost minimal and are essential.
Is intramuscular injection more effective?
No. Intramuscular produces faster absorption but similar or reduced GH response. Causes more tissue trauma and discomfort. Subcutaneous is the standard.
How deep should needle go?
Target 1/4 to 1/2 inch depth depending on body composition, reaching subcutaneous fat layer without penetrating muscle beneath.